Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Pharmacy Regulation Compounding topic
No spam. Unsubscribe anytime.
Texas veterinary board clarifies rule allowing compounded controlled substances for clinic use
Summary
At its April meeting the Texas Board of Veterinary Medical Examiners told licensees there is no rule banning compounded controlled substances for office stock, but stressed that any medication dispensed for a specific patient to take home must be prescribed and documented as a separate prescription.
The Texas Board of Veterinary Medical Examiners on April 15 clarified that its existing rule (cited at the meeting as rule 573.44) does not prohibit veterinarians from obtaining compounded controlled-substance products for multiuse office stock, but that medications dispensed for a specific patient to go home must be issued as a separate prescription following dispensing rules.
Board General Counsel Kelly Phelps told members and the public, “in our current rule, there is nothing that prohibits such a thing,” referring to compounded controlled substances ordered for clinic stock. Phelps added the board’s rule does bar using clinic stock as a substitute for a patient-specific prescription when medication is to leave the clinic.
The clarification followed public comment from Mike Giuliano of Epicure Pharma, an outsourcing facility that supplies veterinary products. Giuliano asked the board to state whether rule 573.44 “prohibits a veterinarian from ordering a compounded multiuse vial of a controlled substance for office use,” saying many veterinarians believed the board’s position was restrictive.
“Outsourcing facilities meet cGMP rather than USP standards,” Giuliano said, arguing outsourcing facilities also hold DEA manufacturing licenses and can legally supply some controlled products that retail pharmacies cannot. He asked the board to confirm that veterinarians may order those products for clinic use.
Board President Steven Gola said he could not point to a prior board ruling that had created the misconception and thanked the public for raising the issue so staff could provide clarification. The board and staff said they plan to publish a one-page guidance document for the website and make the interpretation available to licensees.
The board staff emphasized the regulatory distinction: clinic stock may be maintained and used in-office under the agency’s rules, but if a clinician dispenses medication for a particular patient to take home, that medication must be prescribed and documented as a discrete prescription in accordance with controlled-substance dispensing rules. Staff said they would post the guidance on the agency website.
No formal vote was taken; the item was presented as an informational clarification and staff follow-up (a guidance one-pager) was announced.
